MR 409|cas:1445155-39-4|西域试剂

MR 409,99.90%

产品编号：Bellancom-P3304| CAS NO：1445155-39-4| 分子式：C₁₅₃H₂₅₂N₄₄O₄₃| 分子量：3395.91

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P3304		￥12800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MR 409

产品介绍

MR 409 是一种选择性的生长激素释放激素 (GHRH) 激动剂。MR 409 通过增强脑缺血小鼠的内源性神经发生而具有显著的神经保护作用。MR 409 还可以抑制肺癌的体内生长。

生物活性

MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer^[4].

体外研究

One week post-myocardial infarction (MI), MR 409 (MR-409) significantly reduces plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo.
MR 409 (MR-409; 1 μM) suppresses p53 expression in bovine pulmonary arterial endothelial cells (BPAECs).
MR 409 (1 μM) induces the activation of JAK2, STAT3 and ERK1/2.
MR 409 (MR-409; 1 and 5 μM) decreases LPS-induced PGE₂ and 8-iso-PGF_2α levels, in a dose-dependent manner.
MR 409 (1 and 5μM) decreases LPS-induced lactate dehydrogenase (LDH) activity and nitrite production, without showing a dose-dependent effect.
MR 409 (1 and 5 μM) decreases LPS-induced gene expression of COX-2, NF-κB and iNOS in colon specimens, without a dose-dependent effect.
MR 409 (MR-409) can stimulate endogenous neurogenesis and improve the tMCAO-induced loss of neuroplasticity. MR 409 also enhances the proliferation and inhibits apoptosis of neural stem cells treated with oxygen and glucose deprivation-reperfusion^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	BPAEC
Concentration:	1 μM
Incubation Time:	24, 48 and 72 hours
Result:	Significantly suppressed p53 expression levels after 48 and 72 hours of treatment.

体内研究
(In Vivo)

MR 409 (MR-409) inhibits the in vivo growth of lung cancer xenografted into nude mice.
MR 409 (5 μg; s.c. treated daily for 4 weeks) reduces nociceptive response in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult C57/BL6 male mice (5 weeks old, weight 20-22 g)
Dosage:	5 µg
Administration:	Treated daily by subcutaneous (s.c.) administration of 0.1 mL solution
Result:	Showed maximal antinociceptive effects at 2 weeks. Sustained a moderate analgesic effect at 4 weeks.

体内研究

MR 409 (MR-409) inhibits the in vivo growth of lung cancer xenografted into nude mice.
MR 409 (5 μg; s.c. treated daily for 4 weeks) reduces nociceptive response in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult C57/BL6 male mice (5 weeks old, weight 20-22 g)
Dosage:	5 µg
Administration:	Treated daily by subcutaneous (s.c.) administration of 0.1 mL solution
Result:	Showed maximal antinociceptive effects at 2 weeks. Sustained a moderate analgesic effect at 4 weeks.

体内研究

MR 409 (MR-409) inhibits the in vivo growth of lung cancer xenografted into nude mice.
MR 409 (5 μg; s.c. treated daily for 4 weeks) reduces nociceptive response in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult C57/BL6 male mice (5 weeks old, weight 20-22 g)
Dosage:	5 µg
Administration:	Treated daily by subcutaneous (s.c.) administration of 0.1 mL solution
Result:	Showed maximal antinociceptive effects at 2 weeks. Sustained a moderate analgesic effect at 4 weeks.